Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ? (TNF?) or Tissue Factor protein (which may be truncated).
Type:
Grant
Filed:
July 14, 2010
Date of Patent:
July 22, 2014
Assignee:
Philogen S.p.A.
Inventors:
Luciano Zardi, Dario Neri, Barbara Carnemolla, Fredrik Nilsson, Lorenzo Tarli, Laura Borsi, Cornelia Halin
Abstract: The invention provides a blocking ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex, for sequential use in inhibiting the growth of tumour cell
Abstract: Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient.
Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
Type:
Application
Filed:
October 4, 2013
Publication date:
May 15, 2014
Applicant:
PHILOGEN S.P.A.
Inventors:
Dario NERI, Barbara CARNEMOLLA, Annalisa SIRI, Enrica BALZA, Patrizia CASTELLANI, Luciano ZARDI, Gregory Paul WINTER, Giovanni NERI, Laura BORSI, Alessandro PINI
Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
Type:
Grant
Filed:
August 21, 2007
Date of Patent:
April 22, 2014
Assignee:
Philogen S.p.A.
Inventors:
Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
Type:
Grant
Filed:
August 2, 2010
Date of Patent:
March 25, 2014
Assignee:
Philogen S.p.A.
Inventors:
Manuela Kaspar, Christoph Schliemann, Dario Neri
Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration. and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12(IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ?(TNF?) or Tissue Factor protein (which may be truncated).
Type:
Grant
Filed:
February 22, 2001
Date of Patent:
January 7, 2014
Assignee:
Philogen S.p.A.
Inventors:
Luciano Zardi, Dario Neri, Barbara Carnemolla, Fredrik Nilsson, Lorenzo Tarli, Laura Borsi, Cornelia Halin
Abstract: In one aspect, there is provided a protein-drug conjugate compound comprising a protein covalently attached by a linker to one or more drug moieties, wherein the linker has a half-life of from 1 hour to 50 hours in phosphate buffered saline at 37° C. A carbonyl derivative of LU103793 is also described that can be used in a protein-drug conjugate compound comprising an antibody covalently attached by a linker to the drug moiety comprising, consisting or consisting essentially of the carbonyl derivative.
Abstract: Immunocytokine comprising cytokine, e.g. interleukin 2 (IL-2), conjugated to antibody against tumour neovasculature antigen, e.g. tenascin-C, for use in combination therapy with chemotherapeutic agent such as temozolomide. Use of immunocytokine and chemotherapy for treatment of tumours e.g. glioblastoma and other cancers.
Abstract: The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
Type:
Grant
Filed:
March 11, 2003
Date of Patent:
July 23, 2013
Assignees:
Philogen S.p.A., Bayer Schering Pharma AG
Inventors:
Laura Borsi, Barbara Carnemolla, Enrica Balza, Patrizia Castellani, Luciano Zardi, Matthias Friebe, Christoph-Stephan Hilger
Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the treatment of tumour metastases.
Type:
Grant
Filed:
August 9, 2012
Date of Patent:
July 9, 2013
Assignee:
Philogen S.p.A.
Inventors:
Jascha-Nikolai Rybak, Christoph Rosli, Alessandra Villa, Giovanni Neri, Dario Neri
Abstract: Conjugate for targeting therapeutic or diagnostic agent or drug to cells or tissues in a body, e.g. areas of neoplastic growth or angiogenesis. Use of conjugate for in vivo diagnosis or therapy e.g. inhibiting tumor growth or metastasis, inhibiting angiogenesis and/or treating cancer. Conjugate comprises therapeutic or diagnostic agent as oligomeric protein e.g. heterodimeric protein, wherein first and second subunits of protein are each conjugated to a specific binding member e.g. an antibody fragment such as scFv. Subunits of oligomer may be conjugated to specific binding members as fusion proteins. Conjugate may comprise IL-12 heterodimer having two subunits, each subunit fused to scFv L19 or TN11 for targeting IL-12 to extracellular matrix components associated with neoplastic growth and angiogenesis.
Abstract: This invention relates to the treatment of cancer using anti-cancer agents, such as doxorubicin or paclitaxel, in combination with antibody-interleukin 2 (IL2) conjugates which target tenascin-C.
Abstract: The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.
Abstract: Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member.
Abstract: Immunocytokine comprising cytokine, e.g. interleukin 2 (IL-2), conjugated to antibody against tumour neovasculature antigen, e.g. tenascin-C, for use in combination therapy with chemotherapeutic agent such as temozolomide. Use of immunocytokine and chemotherapy for treatment of tumours e.g. glioblastoma and other cancers.
Abstract: Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.
Type:
Grant
Filed:
October 31, 2005
Date of Patent:
June 28, 2011
Assignee:
Philogen S.p.A.
Inventors:
Simon Brack, Michela Silacci, Dario Neri
Abstract: An apparatus (1) for preparing medicines containing radioactive substances, more specifically injectable medicines containing beta-emitting substances, in which a radioactive element is combined, in a mixture, with a protein to be labelled using the radioactive element; the mixture is then subjected to a chromatographic separation step which separates the mixture and isolates the medicine (16).
Abstract: The invention refers to the use of L19IL2 for treatment of pancreatic cancer. In another embodiment, the invention relates to a combination (i) of a fusion protein, comprising an Interleukin 2 part and an antibody part, specifically recognizing the extra domain B of fibronectin (ED-B-fibronectin), and (ii) gemcitabine.
Type:
Grant
Filed:
April 4, 2007
Date of Patent:
December 14, 2010
Assignee:
Philogen S.p.A.
Inventors:
Andreas Menrad, Hans Dietrich Menssen, Karola Wagner